These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19451331)

  • 21. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
    Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic complications in HIV infection. In search of underlying mechanisms.
    Johnson DL
    Adv Nurse Pract; 2002 Jul; 10(7):45-50, 76. PubMed ID: 12420551
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.
    Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P
    Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk?
    Gilleece Y; Nelson M
    J HIV Ther; 2001 May; 6(2):37-9. PubMed ID: 11501202
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications of HIV disease and antiretroviral therapy.
    Currier JS; Havlir DV
    Top HIV Med; 2005; 13(1):16-23. PubMed ID: 15849369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal].
    Diouf A; Cournil A;
    Bull Soc Pathol Exot; 2014 Oct; 107(4):234-7. PubMed ID: 24683016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What should we know about metabolic syndrome and lipodystrophy in AIDS?
    Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A
    Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complications of HIV disease and antiretroviral therapy.
    Currier JS; Havlir DV
    Top HIV Med; 2009; 17(2):57-67. PubMed ID: 19401608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disorders of glucose metabolism in the context of human immunodeficiency virus infection.
    Larson R; Capili B; Eckert-Norton M; Colagreco JP; Anastasi JK
    J Am Acad Nurse Pract; 2006 Mar; 18(3):92-103. PubMed ID: 16499742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
    Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
    AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
    Resino S; Palladino C; Lorente R; Micheloud D; Bellón JM; Larru B; Gutiérrez MD; de José MI; Polo R; Muñoz-Fernández MA;
    Pediatr Infect Dis J; 2010 Aug; 29(8):774-7. PubMed ID: 20375850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [HIV-related cardiovascular risk factors].
    Masiá M; Gutiérrez F
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():17-23. PubMed ID: 20172411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular disease in HIV-positive patients.
    Kamin DS; Grinspoon SK
    AIDS; 2005 Apr; 19(7):641-52. PubMed ID: 15821390
    [No Abstract]   [Full Text] [Related]  

  • 40. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.